Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

1373 - Clinical efficacy of eribulin as first- or second-line treatment for patients with recurrent HER2-negative breast cancer: a phase II randomized study (JBCRG-19)

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Ken-ichi Watanabe

Citation

Annals of Oncology (2018) 29 (suppl_8): viii90-viii121. 10.1093/annonc/mdy272

Authors

K. Watanabe1, K. Aogi2, M. Kitada3, T. Sangai4, S. Ohtani5, T. Aruga6, H. Kawaguchi7, T. Fujisawa8, S. Maeda9, T. Morimoto10, S. Morita11, N. Masuda12, M. Toi13, S. Ohno14

Author affiliations

  • 1 Breast Surgery, Hokkaido Cancer Center, 003-0804 - Sapporo/JP
  • 2 Breast Oncology, Shikoku Cancer Center, 791-0280 - Matsuyama/JP
  • 3 Breast Disease Center, Asahikawa Medical University Hospital, Asahikawa/JP
  • 4 General Surgery, Chiba University Graduate School of Medicine, 260-8677 - Chiba/JP
  • 5 Breast Surgery, Hiroshima City Hospital, 730-0011 - Hiroshima/JP
  • 6 Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo/JP
  • 7 Breast Surgery, Matsuyama Red Cross Hospital, 790-8524 - Matsuyama/JP
  • 8 Breast Oncology, Gunma Prefectural Cancer Center, Gunma/JP
  • 9 Breast Surgery, National Nagasaki Medical Center, Omura/JP
  • 10 Breast Surgery, Yao Municipal Hospital, 581-0069 - Yao/JP
  • 11 Biomedical Statistics And Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto/JP
  • 12 Breast Surgery, National Hospital Organization Osaka National Hospital, 540-0006 - Osaka/JP
  • 13 Surgery, Kyoto University-Graduate school of medicine, 606-8507 - Kyoto/JP
  • 14 Breast Oncology Center, The Cancer Institute Hospital of JFCR, Tokyo/JP
More

Resources

Abstract 1373

Background

Anthracycline- or taxane-based regimens are the standard early-line chemotherapy for metastatic breast cancer. However, adverse effects of these treatments, such as neutropenia, peripheral neuropathy, edema, and alopecia, are a concern. The EMBRACE study has shown that eribulin is effective for metastatic breast cancer, even as a late-line treatment. The aim of this study was to investigate the usefulness of eribulin as first- or second-line treatment.

Methods

Patients with recurrent HER2-negative breast cancer who had received previous chemotherapy including both an anthracycline and a taxane were eligible for this phase II study. They were randomly allocated to receive eribulin or treatment of physician’s choice (TPC) as first- or second-line treatment. TPC was selected in advance from paclitaxel, docetaxel, nab-paclitaxel, and vinorelbine. The primary endpoint was progression-free survival (PFS). Secondary endpoints included time to treatment failure (TTF), response rate (RR), duration of response, and safety. (UMIN000009886).

Results

From May 2013 to January 2017, 72 patients were enrolled. The full analysis set comprised data from 58 patients (median age, 58 years; range, 33–82 years); 38 (65.5%) received first-line treatment and 20 (34.5%) received second-line treatment. 43 patients (74.1%) were ER- positive. The per protocol set comprised data from 57 patients. PFS, TTF, RR, and duration of response in both groups are shown in the table. The most common grade 3 or worse adverse events were neutropenia (6/27 [22.2%] in the eribulin group versus 5/31[16.1%] in the TPC group). The incidence of sensory neuropathy was low in both groups.Table: 317P

Eribulin (n = 26)TPC (n = 31)p-value
PFSMedian(M)6.6(5.0-8.1)4.2(0.8-7.6)0.273
TTFMedian(M)6.0(4.7-7.3)3.6(2.3-4.9)0.131
Tumor responseCR0(0.0%)0(0.0%)0.190
PR5(19.2%)6(19.4%)
SD16(61.5%)11(35.5%)
PD5(19.2%)13(41.9%)
ORR5(19.2%)6(19.4%)
Duration of responseMedian(M)3.0(2.1-3.9)2.8(2.4-3.3)0.794

Conclusions

Eribulin was not shown to be superior to TPC in terms of efficacy. However, patients in the eribulin group had slightly longer PFS and TTF.

Clinical trial identification

UMIN000009886.

Legal entity responsible for the study

Japan Breast Cancer Research Group (JBCRG).

Funding

Japan Breast Cancer Research Group (JBCRG).

Editorial Acknowledgement

Disclosure

K. Aogi: Honoraria: Chugai, Eisai, Sanofi, AstraZeneca, Taiho, Daiichi Sankyo, Ono, Otsuka, Nihon Medi-physics, Terumo, Becton Dickinson and Company; Research funding: Chugai, Eisai, Takeda and Sanofi. S. Ohtani: Speakers bureau: Chugai and Eisai. H. Kawaguchi: Honoraria: Chugai, AstraZeneca, Eisai, Kyowa-Kirin, Novartis, Taiho, Pfizer and Nippon Chemiphar; Consulting or advisory role: Chugai and AstraZeneca; Speakers bureau: Chugai, AstraZeneca, Eisai, Kyowa-Kirin, Novartis, Taiho, Pfizer and Nippon Chemiphar. S. Morita: Honoraria: Eisai and Taiho; Research funding: Eisai. N. Masuda: Honoraria: Chugai, Takeda, Pfizer and AstraZeneca; Research funding: Chugai, AstraZeneca, Kyowa-Kirin, MSD, Novartis, Pfizer, Eli-Lilly. M. Toi: Honoraria: Novartis, MSD, Takeda, AstraZeneca, Eisai, Genomic Health, Chugai, Taiho, Bayer, Eli Lilly, Daiichi Sankyo, Kiowa-Kirin, C&C Research Laboratories, Yakult, Sanofi, Shimadzu, Pfizer; Consulting or advisory role: Daiichi Sankyo, Kiowa-Kirin and Taiho; Research funding: Taiho, Chugai, Shimadzu, Astellas Phama, AFI technology and C&C Research Laboratories. S. Ohno: Speakers bureau: Chugai Pharmaceutical, Eisai, Pfizer, Novartis, Taiho, Kyowa-Kirin, AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.